An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections

M.A. Aldeyab; J.C. McElnay; M.G. Scott; C. Edwards; Elizabeth  Davies; F.W. Darwish Elhajji; G. Conlon; F.A. Magee; P.J. Barr; M.P. Kearney

doi:10.1086/660203

An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections

M.A. Aldeyab, J.C. McElnay, M.G. Scott, C. Edwards, Elizabeth Davies, F.W. Darwish Elhajji, G. Conlon, F.A. Magee, P.J. Barr, M.P. Kearney

Dept of Mgmt, Leadership & Marketing

Research output: Contribution to journal › Letter › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	631-633
Number of pages	3
Journal	Infection Control and Hospital Epidemiology
Volume	32
Issue number	6
DOIs	https://doi.org/10.1086/660203
Publication status	Published (in print/issue) - Jun 2011

Bibliographical note

Cited By :7

Export Date: 15 September 2018

CODEN: ICEPE

Correspondence Address: Aldeyab, M. A.; Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, BT9 7BL Belfast, Northern Ireland, United Kingdom; email: [email protected]

Chemicals/CAS: immunoglobulin, 9007-83-4; metronidazole, 39322-38-8, 443-48-1; vancomycin, 1404-90-6, 1404-93-9; Bacterial Toxins; Enterotoxins; Immunoglobulins, Intravenous; Immunologic Factors; tcdA protein, Clostridium difficile

References: Thompson, I., Clostridium difficile-associated disease: Update and focus on non-antibiotic strategies (2008) Age Ageing, 37, pp. 14-18; McFarland, L.V., Update on the changing epidemiology of Clostridium difficile-associated disease (2008) Nat Clin Pract Gastroenterol Hepatol, 5, pp. 40-48; Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A (2000) N Engl J Med, 342, pp. 390-397; Leffler, D.A., Lamont, J.T., Treatment of Clostridium difficile-associated disease (2009) Gastroenterology, 136, pp. 1899-1912; Gerding, D.N., Muto, C.A., Owens, R.C., Treatment of Clostridium difficile infection (2008) Clin Infect Dis, 46 (1), pp. S32-S42; Halsey, J., Current and future treatment modalities for Clostridium difficile-associated disease (2008) Am J Health Syst Pharm, 65, pp. 705-715; O'Horo, J., Safdar, N., The role of immunoglobulin for the treatment of Clostridium difficile infection: A systematic review (2009) Int J Infect Dis, 13, pp. 663-667; Aldeyab, M.A., Devine, M.J., Flanagan, P., Multi-hospital outbreak of Clostridium difficile ribotype 027 infection: Epidemiology and analysis of control measures (2011) Infect Control Hosp Epidemiol, 32 (3), pp. 210-219; Tobacman, J.K., Assessment of comorbidity: A review (1994) Clin Perform Qual Health Care, 2, pp. 23-32

Keywords

immunoglobulin
metronidazole
vancomycin
aged
clinical article
Clostridium difficile infection
controlled study
human
length of stay
letter
male
single drug dose
treatment outcome
Aged, 80 and over
Bacterial Toxins
Clostridium difficile
Clostridium Infections
Enterotoxins
Female
Humans
Immunoglobulins, Intravenous
Immunologic Factors
Length of Stay
Male
Retrospective Studies
Treatment Outcome

Access to Document

10.1086/660203

https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957937615&doi=10.1086%2f660203&partnerID=40&md5=d70950ff2de7908593fcb24077383224

Cite this

Aldeyab, M. A., McElnay, J. C., Scott, M. G., Edwards, C., Davies, E., Darwish Elhajji, F. W., Conlon, G., Magee, F. A., Barr, P. J., & Kearney, M. P. (2011). An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections. Infection Control and Hospital Epidemiology, 32(6), 631-633. https://doi.org/10.1086/660203

@article{4169975d2b8545fcb5c02c484992fad4,

title = "An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections",

keywords = "immunoglobulin, metronidazole, vancomycin, aged, clinical article, Clostridium difficile infection, controlled study, human, length of stay, letter, male, single drug dose, treatment outcome, Aged, 80 and over, Bacterial Toxins, Clostridium difficile, Clostridium Infections, Enterotoxins, Female, Humans, Immunoglobulins, Intravenous, Immunologic Factors, Length of Stay, Male, Retrospective Studies, Treatment Outcome",

author = "M.A. Aldeyab and J.C. McElnay and M.G. Scott and C. Edwards and Elizabeth Davies and {Darwish Elhajji}, F.W. and G. Conlon and F.A. Magee and P.J. Barr and M.P. Kearney",

note = "Cited By :7 Export Date: 15 September 2018 CODEN: ICEPE Correspondence Address: Aldeyab, M. A.; Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, BT9 7BL Belfast, Northern Ireland, United Kingdom; email: [email protected] Chemicals/CAS: immunoglobulin, 9007-83-4; metronidazole, 39322-38-8, 443-48-1; vancomycin, 1404-90-6, 1404-93-9; Bacterial Toxins; Enterotoxins; Immunoglobulins, Intravenous; Immunologic Factors; tcdA protein, Clostridium difficile References: Thompson, I., Clostridium difficile-associated disease: Update and focus on non-antibiotic strategies (2008) Age Ageing, 37, pp. 14-18; McFarland, L.V., Update on the changing epidemiology of Clostridium difficile-associated disease (2008) Nat Clin Pract Gastroenterol Hepatol, 5, pp. 40-48; Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A (2000) N Engl J Med, 342, pp. 390-397; Leffler, D.A., Lamont, J.T., Treatment of Clostridium difficile-associated disease (2009) Gastroenterology, 136, pp. 1899-1912; Gerding, D.N., Muto, C.A., Owens, R.C., Treatment of Clostridium difficile infection (2008) Clin Infect Dis, 46 (1), pp. S32-S42; Halsey, J., Current and future treatment modalities for Clostridium difficile-associated disease (2008) Am J Health Syst Pharm, 65, pp. 705-715; O'Horo, J., Safdar, N., The role of immunoglobulin for the treatment of Clostridium difficile infection: A systematic review (2009) Int J Infect Dis, 13, pp. 663-667; Aldeyab, M.A., Devine, M.J., Flanagan, P., Multi-hospital outbreak of Clostridium difficile ribotype 027 infection: Epidemiology and analysis of control measures (2011) Infect Control Hosp Epidemiol, 32 (3), pp. 210-219; Tobacman, J.K., Assessment of comorbidity: A review (1994) Clin Perform Qual Health Care, 2, pp. 23-32",

year = "2011",

month = jun,

doi = "10.1086/660203",

language = "English",

volume = "32",

pages = "631--633",

journal = "Infection Control and Hospital Epidemiology",

issn = "0899-823X",

publisher = "Cambridge University Press",

number = "6",

}

Aldeyab, MA, McElnay, JC, Scott, MG, Edwards, C, Davies, E, Darwish Elhajji, FW, Conlon, G, Magee, FA, Barr, PJ & Kearney, MP 2011, 'An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections', Infection Control and Hospital Epidemiology, vol. 32, no. 6, pp. 631-633. https://doi.org/10.1086/660203

TY - JOUR

T1 - An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections

AU - Aldeyab, M.A.

AU - McElnay, J.C.

AU - Scott, M.G.

AU - Edwards, C.

AU - Davies, Elizabeth

AU - Darwish Elhajji, F.W.

AU - Conlon, G.

AU - Magee, F.A.

AU - Barr, P.J.

AU - Kearney, M.P.

N1 - Cited By :7 Export Date: 15 September 2018 CODEN: ICEPE Correspondence Address: Aldeyab, M. A.; Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, BT9 7BL Belfast, Northern Ireland, United Kingdom; email: [email protected] Chemicals/CAS: immunoglobulin, 9007-83-4; metronidazole, 39322-38-8, 443-48-1; vancomycin, 1404-90-6, 1404-93-9; Bacterial Toxins; Enterotoxins; Immunoglobulins, Intravenous; Immunologic Factors; tcdA protein, Clostridium difficile References: Thompson, I., Clostridium difficile-associated disease: Update and focus on non-antibiotic strategies (2008) Age Ageing, 37, pp. 14-18; McFarland, L.V., Update on the changing epidemiology of Clostridium difficile-associated disease (2008) Nat Clin Pract Gastroenterol Hepatol, 5, pp. 40-48; Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A (2000) N Engl J Med, 342, pp. 390-397; Leffler, D.A., Lamont, J.T., Treatment of Clostridium difficile-associated disease (2009) Gastroenterology, 136, pp. 1899-1912; Gerding, D.N., Muto, C.A., Owens, R.C., Treatment of Clostridium difficile infection (2008) Clin Infect Dis, 46 (1), pp. S32-S42; Halsey, J., Current and future treatment modalities for Clostridium difficile-associated disease (2008) Am J Health Syst Pharm, 65, pp. 705-715; O'Horo, J., Safdar, N., The role of immunoglobulin for the treatment of Clostridium difficile infection: A systematic review (2009) Int J Infect Dis, 13, pp. 663-667; Aldeyab, M.A., Devine, M.J., Flanagan, P., Multi-hospital outbreak of Clostridium difficile ribotype 027 infection: Epidemiology and analysis of control measures (2011) Infect Control Hosp Epidemiol, 32 (3), pp. 210-219; Tobacman, J.K., Assessment of comorbidity: A review (1994) Clin Perform Qual Health Care, 2, pp. 23-32

PY - 2011/6

Y1 - 2011/6

KW - immunoglobulin

KW - metronidazole

KW - vancomycin

KW - aged

KW - clinical article

KW - Clostridium difficile infection

KW - controlled study

KW - human

KW - length of stay

KW - letter

KW - male

KW - single drug dose

KW - treatment outcome

KW - Aged, 80 and over

KW - Bacterial Toxins

KW - Clostridium difficile

KW - Clostridium Infections

KW - Enterotoxins

KW - Female

KW - Humans

KW - Immunoglobulins, Intravenous

KW - Immunologic Factors

KW - Length of Stay

KW - Male

KW - Retrospective Studies

KW - Treatment Outcome

U2 - 10.1086/660203

DO - 10.1086/660203

M3 - Letter

SN - 0899-823X

VL - 32

SP - 631

EP - 633

JO - Infection Control and Hospital Epidemiology

JF - Infection Control and Hospital Epidemiology

IS - 6

ER -